GLP-1 Market Share by Company
Track the global GLP-1 sector. Eli Lilly and Novo Nordisk dominate class revenue while late-stage challengers race oral, monthly, and combination assets to market. The investment story spans peptide CDMOs, autoinjector device makers, payers reshaping access (Medicare Part D, the CMS GLP-1 Bridge, IRA negotiation), and cross-sector adjacencies (CPG, life insurance, MASH).
The GLP-1 sector on Sterling tracks 28 companies.
GLP-1 Sector at a Glance
Global GLP-1 Class Sales by Brand
US Prescription Volume by Molecule
Class Sales Forecast by Indication (2026 to 2030)
Public-Equity Universe by Archetype
Incumbents
The two-player market. Captured the vast majority of class revenue in 2025.
Late-stage challengers
Diversified pharma entering through M&A or licensing. Different unit economics from incumbents.
Combination adjunct
Sells alongside a GLP-1 rather than against it. Regeneron's trevogrumab targets the lean-mass loss that comes with GLP-1 weight loss.
Mid- and small-cap pure-plays
High-upside, binary readouts. M&A-prone given big-pharma demand for assets.
Distribution and MASH-adjacent
Telehealth distribution channel plus MASH-adjacent therapeutics that overlap with GLP-1 in the same disease.
Supply chain and device
Peptide CDMO (Bachem), sterile fill-finish capacity (Thermo Fisher), injectable components (West), autoinjector pens (Ypsomed), and the diabetes-device layer around the class (Insulet, Dexcom).
US distribution and payer access
Volume without much margin for the big three wholesalers, plus CVS Caremark, whose formulary decisions move GLP-1 share between Novo and Lilly.
International and private
Innovent: first dual GCG/GLP-1 approved globally (Lilly partnership). Boehringer Ingelheim: largest private GLP-1 player (survodutide Phase 3 with Zealand).
End-to-End Supply Chain
Peptide API
Fill-finish CDMO
Device assembly
Brand
Wholesale distribution
Channel
Patient indication
Catalyst Calendar (Next 18 Months)
- 2026-Q2FDA ApprovalOrforglipron FDA decisionEli Lilly (LLY)First oral non-peptide GLP-1 RA. ATTAIN-1: 12.4% weight loss at 72 weeks (36 mg dose).
- 2026-H1Label ExpansionTirzepatide MACE label expansionEli Lilly (LLY)Triggers Medicare Part D coverage for tirzepatide CV indication.
- 2026-06-29RulemakingFDA 503B bulk substances comment period closesFDAEffectively ends large-scale compounding for semaglutide, tirzepatide, liraglutide.
- 2026-07-01Access ProgramCMS GLP-1 Bridge launchesCMS$50 per month copay for eligible Medicare beneficiaries through Dec 31, 2027.
- 2026-latePivotal ReadoutAmgen MariTide Phase 3 readoutAmgen (AMGN)Differentiated antibody-peptide conjugate, monthly dosing. Phase 3 readout expected late 2026; BLA filing late 2026 to early 2027.
- 2026-H2FDA ApprovalCagriSema FDA decisionNovo Nordisk (NVO)Cagrilintide + semaglutide combo. About 22.7% mean weight loss in Phase 3a.
- 2026Trial ReadoutPemvidutide MASH IMPACT Phase 2b dataAltimmune (ALT)MASH-first GLP-1 / glucagon dual agonist. Phase 2b IMPACT 48-week data; pivotal Phase 3 (PERFORMA) planned for 2026.
- 2027-01-01PricingIRA negotiated semaglutide price effectiveCMSMaximum fair price for Ozempic, Wegovy, Rybelsus in Medicare Part D.
Companies in the GLP-1 sector (28)
- Eli Lilly
- Novo Nordisk
- Pfizer
- Amgen
- Roche
- AstraZeneca
- Viking Therapeutics
- Structure Therapeutics
- Altimmune
- Zealand Pharma
- Hims & Hers Health
- Madrigal Pharmaceuticals
- Akero Therapeutics
- Bachem
- Ypsomed
- Innovent Biologics
- Boehringer Ingelheim
- Merck & Co.
- AbbVie
- Regeneron Pharmaceuticals
- Insulet
- DexCom
- West Pharmaceutical Services
- Thermo Fisher Scientific
- McKesson
- Cencora
- Cardinal Health
- CVS Health
Related sectors
Frequently asked questions
What is the GLP-1 sector?
Track the global GLP-1 sector. Eli Lilly and Novo Nordisk dominate class revenue while late-stage challengers race oral, monthly, and combination assets to market. The investment story spans peptide CDMOs, autoinjector device makers, payers reshaping access (Medicare Part D, the CMS GLP-1 Bridge, IRA negotiation), and cross-sector adjacencies (CPG, life insurance, MASH).
Which companies lead the GLP-1 sector?
Sterling tracks 28 companies in GLP-1, led by Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
How can I invest in the GLP-1 sector?
Publicly traded names in GLP-1 include Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN) and Roche (RHHBY). Compare them side by side on Sterling. Data last updated May 31, 2026.
